Alternatives to albumin: Starch replacement for plasma exchange

Journal of Clinical Apheresis

Volumn 12, Issue 3, 1997, Pages 146-153

  Brecher, M E ^a   Owen, H G ^a   Bandarenko, N ^a  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

Apheresis; Colloid; Hespan; Hetastarch; Hydroxyethyl starch; Pentaspan; Pentastarch; Plasma exchange; Plasmapheresis; Replacement

Indexed keywords

ALBUMIN; HETASTARCH; PLASMA SUBSTITUTE; SODIUM CHLORIDE;

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; HUMAN; LEUKAPHERESIS; PLASMAPHERESIS; PRURITUS;

ALBUMINS; COSTS AND COST ANALYSIS; HUMANS; PLASMA EXCHANGE; PLASMA SUBSTITUTES; STARCH;

EID: 0030815871     PISSN: 07332459     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-1101(1997)12:3<146::AID-JCA8>3.0.CO;2-A     Document Type: Conference Paper

References (27)

1. Lasky LC, Finnerty EP, Genis L, Polesky HF: Protein and colloid osmotic pressure changes with albumin and/or saline replacement during plasma exchange. Transfusion 24:256-259, 1984.
2. McLeod, Sassetti, Stefoski, Davis: Partial plasma protein replacement in therapeutic plasma exchange. J Clin Apheresis 1:115-118, 1983.
3. Vermeulen LC, Ratko TA, Erstad BL, Brecher ME, Matuszewski KA: A paradigm for consensus: The University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions. Arch Int Med 155:373-379, 1995.
4. Trieb J, Haass A, Pindur G, Grauer MT, Wenzel E, Schimrigk K: All medium starches are not the same: Influence of the degree of hydroxyethyl substitution of hydroxyethyl starch on plasma volume, hemorrheologic conditions, and coagulation. Transfusion 36: 450-455, 1996.
5. Hulse JD, Yacobi A: Hetastarch: An overview of the colloid and its metabolism. Drug Intell Clin Pharm 17:331-341, 1983.
6. Mishler JM, Hester JP, Huestis DW, Rock GA, Strauss RB: Dosage and scheduling regimens for erythrocyte-sedimenting macromolecules. J Clin Apheresis 1:130-143, 1983.
7. Owen HG, Brecher ME: Atypical reactions associated with ACE inhibitors and apheresis. Transfusion 34:891-894, 1994.
8. Brecher ME, Owen HG, Collins ML: Apheresis and ace inhibitors. Transfusion 33:963-964, 1993.
9. Fujii H: Plasma exchange using Dextran 40-electrolyte solution as the sole replacement fluid in malignant paraproteinemia. Transfusion 28:42-45, 1988.
10. Burgstaler EA, Pineda AA: Hydroxyethylstarch as replacement in therapeutic plasma exchange. Prog Clin Biol Res 337:395-397, 1990.
11. Owen HG, Brecher ME: Partial colloid replacement for therapeutic plasma exchange. J Clin Apheresis 12:87-92, 1997.
12. Hester JP, McCredie KB, Freireich EJ: Response to chronic leukapheresis procedures and survival of chronic myelogenous leukemia patients. Transfusion 22:305-307, 1982.
13. Rock G, Sutton DMC, Freedman J, Nair RC: Pentastarch instead of albumin as replacement fluid for therapeutic plasma exchange. J Clin Apheresis (in press).
14. Chang JC, Gross HM, Jang NS: Disseminated intravascular coagulation due to intravenous administration of hetastarch. Am J Med Sci 300:301-303, 1990.
15. Jurecka W, Sz'epfalusi Z, Parth E, Schiemetta W, Gebhart W, Scheiner O, Kraft D: Hydroxyethylstarch deposits in human skin - a model for pruritis? Arch Dermatol Res 285:13-19, 1993.
16. Schneeberger R, Albegger K, Oberasheer G, Miller K: Juckreizeine nebenwirkung von hydroxyäthylstärke (HES)? HNO 38:298-303, 1990.
17. Hermann J, Gall H: Diagnose und therapie des persistierenden pruritis nach infusion von hydroxyäthylstärke (HAS). Aktuel Dermatol 16:166-167, 1990.
18. Parker NE, Porter JB, Williams HJM, Leftley M: Pruritis after administration of hetastarch. BMJ 284:385-386, 1982.
19. Strauss RG: Review of the effects of hydroxyethyl starch on the blood coagulation system. Transfusion 21:299-302, 1981.
20. Trivedi SM, Humphrey RL, Braine HG, Frondoza CG: Hydroxyethyl starch serum levels in leukapheresis donors measured by modified periodic acid-Schiff staining technique. Transfusion 24: 260-263, 1984.
21. Maguire LC, Strauss RG, Koepke JA, Bowman RJ, Zelenski KR, Lambert RM, Hulse JD, Atnip AK: The elimination of hydroxyethyl starch from the blood of donors experiencing single or multiple intermittent-flow centrifugation leukapheresis. Transfusion 21:347-353, 1981.
22. Brecher ME, Owen HG: Washout kinetics of colloidal starch as a partial or full replacement for plasma exchange. J Clin Apheresis 11:123-126, 1996.
23. Power JP, Lawlor E, Davidson F, Yap PL, Kenny Walsh E, Whelton MJ, Walsh TJ: Hepatitis C viraemia in recipients of Irish intravenous anti-D immunoglobulin [letter]. Lancet 343:1166-1167, 1994.
24. Power JP, Lawlor E, Davidson F, Holmes EC, Yap PL, Simmonds P: Molecular epidemiology of an outbreak of infection with hepatitis C virus in recipients of anti-D immunoglobulin. Lancet 345 1211-1214, 1995.
25. Bresee JS, Mast EE, Coleman PJ, Baron MJ, Schonberger LB, Alter MJ, Jonas MM, Yu MW, Renzi PM, Schneider LC: Hepatitis C virus infection associated with administration of intravenous immune globulin. JAMA 276:1563-1567, 1996.
26. Meisel H, Reip A, Faltus B, Lu M, Porst H, Wiese M, Roggendorf M, Krüger DH: Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin. Lancet 345:1209-1211, 1995.
27. Widell A, Zhang YY, Andersson-Gare B, Hammarstrom L: At least three hepatitis C virus strains implicated in Swedish and Danish patients with intravenous immunoglobulin-associated hepatitis C. Transfusion 37:313-320, 1997.